Clinical Trial Update: D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for D-0316 in patients with EGFR-positive non-small cell lung cancer (NSCLC) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• D-0316

Snippet

Sponsor: InventisBio Co., Ltd | Conditions: Solid Tumor, NSCLC | Phase 2 | Status: COMPLETED